Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Hepatocellular carcinoma: transcriptome diversity regulated by RNA editing.

Li Y, Chen L, Chan TH, Guan XY.

Int J Biochem Cell Biol. 2013 Aug;45(8):1843-8. doi: 10.1016/j.biocel.2013.05.033. Epub 2013 Jun 4. Review.

PMID:
23748106
2.

RNA editome imbalance in hepatocellular carcinoma.

Qi L, Chan TH, Tenen DG, Chen L.

Cancer Res. 2014 Mar 1;74(5):1301-6. doi: 10.1158/0008-5472.CAN-13-3485. Epub 2014 Feb 20. Review.

3.

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.

Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L.

Gut. 2014 May;63(5):832-43. doi: 10.1136/gutjnl-2012-304037. Epub 2013 Jun 13.

4.

Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.

Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY.

Nat Med. 2013 Feb;19(2):209-16. doi: 10.1038/nm.3043. Epub 2013 Jan 6.

5.

RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing.

Hu X, Wan S, Ou Y, Zhou B, Zhu J, Yi X, Guan Y, Jia W, Liu X, Wang Q, Qi Y, Yuan Q, Huang W, Liao W, Wang Y, Zhang Q, Xiao H, Chen X, Huang J.

Cancer Lett. 2015 Feb 28;357(2):510-9. doi: 10.1016/j.canlet.2014.12.006. Epub 2014 Dec 8.

PMID:
25499081
6.

Genome-wide identification of RNA editing in hepatocellular carcinoma.

Kang L, Liu X, Gong Z, Zheng H, Wang J, Li Y, Yang H, Hardwick J, Dai H, Poon RT, Lee NP, Mao M, Peng Z, Chen R.

Genomics. 2015 Feb;105(2):76-82. doi: 10.1016/j.ygeno.2014.11.005. Epub 2014 Nov 25.

PMID:
25462863
7.

Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.

Herceg Z, Paliwal A.

Mutat Res. 2011 May-Jun;727(3):55-61. doi: 10.1016/j.mrrev.2011.04.001. Epub 2011 Apr 15. Review.

PMID:
21514401
8.
9.

Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.

Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, van Dekken H.

J Pathol. 2000 Oct;192(2):207-15.

PMID:
11004697
10.

Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma.

Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, Shigehara K, Kanda T, Yoshida H, Uchida E, Tajiri T, Takizawa T.

PLoS One. 2011 Jan 25;6(1):e15304. doi: 10.1371/journal.pone.0015304.

11.

RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma.

Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN.

PLoS One. 2011;6(10):e26168. doi: 10.1371/journal.pone.0026168. Epub 2011 Oct 17.

12.

Epigenetics of hepatocellular carcinoma: a new horizon.

Liu WR, Shi YH, Peng YF, Fan J.

Chin Med J (Engl). 2012 Jul;125(13):2349-60. Review.

PMID:
22882861
13.

Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.

Li S, Mao M.

Cancer Lett. 2013 Nov 1;340(2):247-53. doi: 10.1016/j.canlet.2012.09.027. Epub 2012 Oct 12. Review.

PMID:
23063663
14.

miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.

Fan CG, Wang CM, Tian C, Wang Y, Li L, Sun WS, Li RF, Liu YG.

Oncol Rep. 2011 Nov;26(5):1281-6. doi: 10.3892/or.2011.1375. Epub 2011 Jul 1.

PMID:
21725618
15.

Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects.

Kao JH, Chen PJ, Chen DS.

Adv Cancer Res. 2010;108:21-72. doi: 10.1016/B978-0-12-380888-2.00002-9. Review.

PMID:
21034965
16.

[Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].

Xue KX.

Ai Zheng. 2005 Jun;24(6):757-68. Review. Chinese.

PMID:
15946497
17.

Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: a detailed analysis of two cases and a review of the literature.

van Dekken H, Wink J, Alers JC, de Man RA, IJzermans JN, Zondervan PE.

Acta Histochem. 2003;105(1):29-41.

PMID:
12666986
18.

The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.

Marotta F, Vangieri B, Cecere A, Gattoni A.

Clin Ter. 2004 May;155(5):187-99. Review.

PMID:
15344567
19.

The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study.

Matsuzaki Y, Sato M, Saito Y, Karube M, Doy M, Shoda J, Abei M, Tanaka N, Hadama T, Kinoshita M.

J Exp Clin Cancer Res. 1999 Sep;18(3):379-89. Erratum in: J Exp Clin Cancer Res 2000 Mar;19(1):125.

PMID:
10606185
20.

DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.

Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH.

Oncogene. 2006 Mar 30;25(14):1991-2003.

PMID:
16301996

Supplemental Content

Support Center